We conducted an expert review of clinical case reports on drug-induced fatty liver disease (DIFLD) to classify drugs according to distinct clinical phenotypes. Seven clusters were identified based on clinical, biochemical, and histological features reflecting drug toxic mechanisms: Cluster 0 (Control): Drugs with no known steatotic effects or clinical evidence of DIFLD. Cluster 1: Drugs with mild pro-steatotic effects, exacerb...